IEX bounces after earnings as put hedge unwinds

IDEX Corporation reported on October 28 and the market appears to have taken the numbers in stride, with the stock recovering to $233.21, up nearly 1% on the day and roughly flat on the week after a rough patch through mid-October.

The options story has now completed its full arc. Two weeks ago this note flagged the put/call ratio at 0.044, the lowest in a year, reflecting heavy call positioning into earnings. That collapsed into a put-heavy stance by October 22, with the ratio spiking to 0.76 before settling at 0.61. That put/call reading sits 1.7 standard deviations above its 20-day mean of 0.23, well above the recent norm, though the 52-week high is 1.87 so the skew is not yet extreme in absolute terms. With the event now in the past and the stock higher, the question is how quickly that defensive positioning gets unwound. Short interest is not adding pressure. Shares short amount to 3.3% of the free float, up roughly 5% on the week but still modest in absolute terms. Borrowing is effectively free at 0.18%, down sharply from around 0.45% three weeks ago. Availability is enormous, with far more shares on offer to borrow than are currently lent out. The lending market is telling a story of benign, low-conviction bearish positioning rather than anything more aggressive.

The Street had been tilting constructively into the print. Oppenheimer lifted its target to $275 last week while maintaining an Outperform. RBC Capital raised to $285, also Outperform, in mid-October. The broader analyst community had been moving targets higher since the Q2 results in late July, with Citigroup, Stifel, and TD Cowen all raising from the $252 to $261 range up to $268 to $275. The mean target of $257 now implies around 10% upside from current levels. The bull case centres on the company's tilt toward high-margin end markets, data centres, semiconductors, pharma and space/defence, where organic orders reportedly rose 28% year on year in Q2 with a book-to-bill of 1.16x. Bears point to tariff timing risk, inventory resets in life sciences and agriculture, and the volatility of shorter-cycle businesses. Valuation sits at a PE of around 24.6x and EV/EBITDA near 17.5x, neither cheap nor stretched for a quality industrial compounder, and the earnings yield factor scores near the middle of the universe at the 49th percentile.

Wikipedia attention for IDEX spiked sharply around the earnings date, with the retail attention z-score reaching 2.63 against its own 90-day history. That is an attention reading, not a revenue signal, and there are no measured leading datasets in the alt data coverage for this name. It reflects the event-driven interest rather than any underlying change in business momentum.

On the ownership register, Wellington Management stands out. The firm filed a 13G/A in May showing its stake had fallen to 2.3% from 8.3% previously, a substantial reduction. Wellington still appears in the top-15 holder list at around 1.1 million shares, but the direction of travel has been clearly lower. BlackRock and Vanguard entities collectively hold above 15% with small additions through Q3, providing a stable index-driven base. No 13D activist is on the register.

The print has landed and the near-term catalyst is now behind the stock. What to watch next is whether the elevated put/call ratio normalises quickly as the hedges expire or roll off, and whether the full-year guidance commentary shifts analyst targets materially ahead of the next scheduled report in early February 2027.